The story of the erectile dysfunction drug presents a intricate picture for investors. While the initial release generated massive returns, the expiration of its exclusive rights opened the floodgates to cheaper alternatives, dramatically diminishing sales. This creates a particular challenge for firms depending on related blockbuster medications,

The legacy of Viagra, and its developer copyright, presents a complex case study for investors. Initially a blockbuster drug, generating billions in revenue , its patent expiration created a wave of knock-off medications, significantly impacting its dominance. While some businesses may try to capitalize on similar conditions , the present landscape